

J.C.

JCWSCS 10 MAY 2004

MAY. 10. 2004 2:00PM

PIPER RUDNICK LLP

FILE COPY

NO. 352

P. 1/7

PIPER RUDNICK LLP  
INTELLECTUAL PROPERTY DEPARTMENT  
One Liberty Place  
1650 Market Street, Suite 4900  
Philadelphia, PA 19103

TELEPHONE (215) 656-3300  
FACSIMILE (215) 656-2498 OR (215) 656-2499  
PROCOMM PLUS (215) 656-2497

FACSIMILE TRANSMITTAL

To: USPTO

Attention: \_\_\_\_\_

Company: USPTO

Facsimile No.: 703-746-9195

From: Carol Coney

Date: May 10, 2004

Re: Filing Reciept Correction

Docket No.: 1414-03

Number of Pages (including cover page):

If you do not receive all the pages or experience any difficulty receiving this transmission,  
please call (215) 656-2412

Additional Instructions/Comments:

Direct Dial 215-656-2412 and fax 215-656-2498 or 2499

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1614  
Examiner :  
Serial No. : 10/735,512  
Filed : December 12, 2003  
Inventor : Salman Al-Mahmood  
Title : ANTISENSE OLIGONUCLEOTIDES  
: CAPABLE OF INHIBITING THE  
: FORMATION OF CAPILLARY TUBES  
: BY ENDOTHELIAL CELLS

Customer No.: 035811

Docket No.: 1414-03

Confirmation No.: 6845

Dated: May 10, 2004

Attn: Application Processing Division  
Customer Correction Branch  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Certificate of Facsimile

For

Request for Corrected Filing Receipt  
Filing Receipt with Corrections Noted in Red  
Supplemental Application Data Sheet  
First Page of the PCT Publication

I hereby certify that this correspondence is being facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.

Name of Applicant, Assignee, Applicant's Attorney  
or Registered Representative:

Piper Rudnick LLP  
Customer No. 035811

By: Date: 10 May 2004

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1614  
Examiner :  
Serial No. : 10/735,512  
Filed : December 12, 2003  
Inventor : Salman Al-Mahmood  
Title : ANTISENSE OLIGONUCLEOTIDES  
: CAPABLE OF INHIBITING THE  
: FORMATION OF CAPILLARY TUBES  
: BY ENDOTHELIAL CELLS

Customer No.: 035811

Docket No.: 1414-03

Confirmation No.: 6845

Dated: May 10, 2004

REQUEST FOR CORRECTED FILING RECEIPT

Attn: Application Processing Division  
Customer Correction Branch  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

We are in receipt of the official filing receipt. A Supplemental Application Data Sheet is enclosed. Under Foreign Applications please change to read "07/14/2001" to -- 06/14/2001 --. Copies of the filing receipt with the corrections noted in red, application data sheet and a copy of the first page of the PCT Publication are enclosed.

We look forward to receiving a corrected filing receipt in due course.

Respectfully submitted,



T. Daniel Christenbury  
Reg. No. 31,750

TDC:cc  
(215) 656-3381



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22312-1450  
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/735,512	12/12/2003	1614	835	1414-03	5	18	2

035811

IP DEPARTMENT OF PIPER RUDNICK LLP  
ONE LIBERTY PLACE, SUITE 4900  
1650 MARKET ST  
PHILADELPHIA, PA 19103

RECEIVED

MAY 07 2004

IP DEPT.

CONFIRMATION NO. 6845

UPDATED FILING RECEIPT

\*OC000000012535034\*

Date Mailed: 05/05/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Salman Al-Mahmood, Paris, FRANCE;

## Assignment For Published Patent Application

Gene Signal, a corporation of France, Evry, FRANCE;

## Domestic Priority data as claimed by applicant

This application is a CON of PCT/FR02/02067 06/14/2002

## Foreign Applications

FRANCE 01/07805 01/14/2001

If Required, Foreign Filing License Granted: 03/19/2004

Projected Publication Date: 08/12/2004

Non-Publication Request: No

Early Publication Request: No

\*\* SMALL ENTITY \*\*

Title

Antisense oligonucleotides capable of inhibiting the formation of capillary tubes by endothelial cells

Preliminary Class

514

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a), unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

(12) DEMANDE INTERNATIONALE PUBLIÉE EN VERTU DU TRAITÉ DE COOPÉRATION  
EN MATIÈRE DE BREVETS (PCT)(19) Organisation Mondiale de la Propriété  
Intellectuelle  
Bureau international(43) Date de la publication internationale  
27 décembre 2002 (27.12.2002)

PCT

(10) Numéro de publication internationale  
WO 02/103014 A2(51) Classification internationale des brevets<sup>7</sup> :  
C12N 15/11, A61K 31/7088, A61P 9/00(21) Numéro de la demande internationale :  
PCT/FR02/02067

(22) Date de dépôt international : 14 juin 2002 (14.06.2002)

(25) Langue de dépôt : français

(26) Langue de publication : français

(30) Données relatives à la priorité :  
0107805 14 juin 2001 (14.06.2001) FR

(71) Déposant et

(72) Inventeur : AL-MAHMOOD, Salman [FR/FR]; 2,  
square Alice, F-75014 Paris (IQ).(74) Mandataires : BREESE, Pierre etc.; Breesé-Majerowicz,  
3, avenue de l'Opéra, F-75001 Paris (FR).(81) États désignés (national) : AE, AG, AL, AM, AT, AU, AZ,  
BA, BE, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ,DE, DK, DM, DZ, EC, EE, ES, FI, GE, GD, GE, GH, GM,  
HR, HU, ID, IL, IN, IS, JP, KB, KG, KP, KR, KZ, LC, LK,  
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,  
MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI,  
SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN,  
YU, ZA, ZM, ZW.(84) États désignés (régional) : brevet ARIPO (GH, GM, KE,  
LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), brevet  
eurasien (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), brevet  
européen (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,  
IE, IT, LU, MC, NL, PT, SE, TR), brevet OAPI (BF, BJ,  
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,  
TD, TG).

Publiée :

sans rapport de recherche internationale, sera republiée  
dès réception de ce rapportEn ce qui concerne les codes à deux lettres et autres abrégia-  
tions, se référer aux "Notes explicatives relatives aux codes et  
abréviations" figurant au début de chaque numéro ordinaire de  
la Gazette du PCT.(54) Title: ANTISENSE OLIGONUCLEOTIDES WHICH CAN INHIBIT THE FORMATION OF CAPILLARY TUBES BY EN-  
DOTHELIAL CELLS(54) Titre : OLIGONUCLEOTIDES ANTISENS CAPABLES D'INHIBER LA FORMATION DES TUBES CAPILLAIRES PAR  
DES CELLULES ENDOTHELIALES(57) Abstract: The invention relates to pharmaceutical compositions which inhibit the formation of capillary tubes by endothelial  
cells, comprising at least one oligonucleotide which can inhibit the expression of the IRS-1 protein. According to the invention,  
the oligonucleotides are embodied as anti-angiogenesis agents. Said pharmaceutical compositions are particularly useful in treating  
angiogenesis-related pathologies.(57) Abrégé : La présente invention a pour objet des compositions pharmaceutiques pour inhiber la formation de tubes capillaires  
par les cellules endothéliales comprenant au moins un oligonucleotide capable d'inhiber l'expression de la protéine IRS-1. Les oli-  
gones sont matérialisés sous la forme d'agents anti-angiogénèse. Lesdites compositions pharmaceutiques sont particulièrement utiles dans le traitement  
de pathologies liées à l'angiogénèse.